Back to top

Leflunomide Tablets

Leflunomide Tablets
Leflunomide Tablets
Send Inquiry
Product Code : 292
Product Description
Each Film Coated Tablet Contains:

Leflunomide BP 20 mg

Indications and Usage for Leflunomide
Leflunomide tablets are used for treating adults who have vigorous rheumatoid arthritis (RA).

Leflunomide Dosage and Administration

Recommended Dosage

The suggested dose of Leflunomide is 20 mg every day. Treatment should be started with or without a high dose, taking in view the patient’s danger of Leflunomide-related hepatotoxicity and Leflunomide-related myelosuppression. The gradual dosage offers gradual-state preparations more quickly.

  • People who are at less risk of Leflunomide-related hepatotoxicity and Leflunomide-related myelosuppression the suggested Leflunomide dose is 100 mg once every day for 3 days. Later to be administered 20 mg once a day.
  • People who are at high risk for Leflunomide-related hepatotoxicity (like those taking associated methotrexate) or Leflunomide-related myelosuppression (like patients taking associated immunosuppressants), the suggested Leflunomide dose is 20 mg once in a day with no need of leaving loading dose.

Leflunomide is contraindicated in:

  • Pregnant women as this may cause harm to fetus. If a woman gets pregnant while using this drug, quit Leflunomide, describe the patient about the possible hazards to the fetus, and start a drug removal procedure.

  • Patients with critical hepatic impairment.

  • Patients with identified allergic reaction to Leflunomide or other ingredients of Leflunomide. Recognized reactions comprise anaphylaxis.

  • Patients being treated with teriflunomide.

Drug Interactions

Following oral administration, Leflunomide is metabolized to an active metabolite, teriflunomide, which is responsible for essentially all of Leflunomide’s in vivo activity. Drug interaction studies have been conducted with both Leflunomide and with its active metabolite, teriflunomide, where the metabolite was directly administered to the test subjects.